Study to Investigate the Pathophysiology of Type 2 Diabetes in Youth

Last updated: January 16, 2018
Sponsor: Yale University
Overall Status: Completed

Phase

N/A

Condition

Stress

Metabolic Syndrome

Diabetes And Hypertension

Treatment

N/A

Clinical Study ID

NCT00536250
0102012241
R01HD040787
  • Ages 8-22
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

The purpose of the study is to determine the role of beta-cell function and insulin resistance in the development of impaired glucose tolerance (IGT) and type 2 diabetes in children and adolescents who have an increased risk of developing type 2 diabetes due to overweight/obesity or a family history of overweight/obesity, diabetes and/or impaired fasting glucose. It is hypothesized that: 1)Obese adolescents with IGT will be more insulin resistant than obese adolescents with NGT. Insulin resistance will be the best predictor of changes in glucose tolerance status., 2)Beta cell function will be impaired in obese adolescents with IGT compared to obese adolescents with NGT., 3)Obese adolescents with IGT will present with greater intramyocellular, intrahepatic and visceral fat than obese adolescents with NGT. Furthermore, obese adolescents with IGT will have larger adipocytes, while having significantly fewer adipocytes compared to obese adolescents with NGT. Obese adolescents with IGT will also have altered expression of key genes related to insulin resistance., and 4)Abnormalities in endothelial function as manifested by low FMD and PAT are already present in obese adolescents with IGT and are linked to insulin resistance.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Lean (not overweight or obese) will be defined as a body mass index (BMI) (kg/m2) lessthan the 85th percentile specific for age and gender, overweight will be defined as aBMI between the 85th and 95th percentiles, and obesity will be defined as a BMIgreater than the 95th percentile1. Following the oral glucose tolerance test (OGTT, 75gm) (HIC #11190), children will be classified as normal glucose tolerant if plasmaglucose at two hours is <140 mg/dl and as impaired glucose tolerant if plasma glucoseis ≥140 mg/dl. To enter the study all children and adults must be in good generalhealth, have a normal medical history and physical exam, and have no endocrinopathies (normal thyroid function test) or other diseases that might affect glucose metabolism.

  • Eligibility will be determined by a comprehensive family and medical history andphysical examination prior to enrollment in the study. Tanner stage of pubic breastand gonadal development will be determined by physical examination and by measurementsof estradiol, testosterone and IGF1 as biochemical markers of pubertal development.

Exclusion

Exclusion Criteria:

  • Medications that are known to alter glucose or insulin metabolism, such as oralsteroids, or certain psychiatric medications, such as Celexa, Lithium and Paxil.Children and adults will be excluded from participating in the PAT test if they have alatex allergy. Lean subjects must have at least one parent, grandparent or siblingwith overweight/obesity (BMI >25), type 2 diabetes, and/or impaired fasting glucose (IFG) (fasting glucose >100 mg/dl). A fasting plasma glucose level will be obtainedvia finger stick in parents of potential volunteers in whom status of diabetes or IFGis unknown. Exclusion criteria also include known diabetes or taking any medicationthat alters liver function and blood pressure. Youth on chronic anti-inflammatorymedications or who consume alcohol are also excluded.

Study Design

Total Participants: 255
Study Start date:
September 01, 2001
Estimated Completion Date:
March 31, 2017

Study Description

Type 2 diabetes is a serious and common chronic disease affecting an estimated 6.6% of the U.S. population 20 to 74 years of age. Among children, type 2 diabetes has previously been reported to account for 2% to 3% of all patients with diabetes mellitus. Recent studies, however, indicate that the prevalence of this disorder is increasing in the pediatric population. This phenomenon parallels the increased prevalence of obesity in children and adolescents, particularly in African-American and Hispanic ethnic groups. Despite the wealth of knowledge concerning the epidemiology, pathophysiology and treatment of type 2 diabetes in adults, we know little about the disease in children.Paralleling the rise in childhood obesity and type 2 diabetes is an increase in the metabolic syndrome in youth. The metabolic syndrome, also known as "Syndrome X," is characterized by hypertension, type 2 diabetes, dyslipidemia and obesity. This syndrome was first described in 1966 by Camus and again by Reaven in 1988. Cook et al. showed that the metabolic syndrome is already present in 6.8% of 12-19 year-olds with a BMI between the 85th and 95th percentiles, and in 28.7% of those with a BMI greater than the 95th percentile. In addition, recent studies from our group suggest that risk factors for type 2 diabetes and the metabolic syndrome are already present in overweight children and adolescents. As the degree of obesity worsens, the prevalence of these risk factors greatly increase.Overweight and obese adolescents with NGT and with IGT will be recruited. Progression from NGT to IGT and from IGT to type 2 diabetes will be assessed by annual oral glucose tolerance tests (OGTT). Comprehensive metabolic assessments will be employed to examine within and between group differences in insulin action and beta-cell function at baseline and during the follow-up.

Connect with a study center

  • 47 College Street

    New Haven, Connecticut 06520
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.